Sanofi CEO Takes Not-So-Slow And Steady Approach To COVID-19 Vaccines
'It's not a race between companies, it's a race against an enemy'
Pfizer and BioNTech may be first out of the gate with robust results for a COVID-19 vaccine but amid all the excitement, Paul Hudson has issued a timely reminder that multiple vaccines will be needed to meet the huge demand.
You may also be interested in...
Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.